omacetaxine (synribo) Report issue

Small molecule Orphan Drug FDA Approved FDA Fast Track FDA Accelerated Approval FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Cephalotaxine is an active metabolite of omacetaxine mepesuccinate also known as omacetaxine. In most patients the levels of cephalotaxine are undetectable. Omacetaxine mepesuccinate is a first-in-class cephalotaxine demonstrating clinical activity in chronic myeloid leukemia.   NCATS

Chemistry

  • SMILES: COC1=C[C@]23CCCN2CCC4=C(C=C5OCOC5=C4)[C@@H]3[C@@H]1O
  • InChIKey: YMNCVRSYJBNGLD-KURKYZTESA-N
  • Mol. Mass: 315.3636
  • ALogP: 2.58
  • ChEMBL Molecule:
    omacetaxine mepesuccinate  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$96.0925 - $126.9500
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

(2'r,3s,4s,5r)-(−)-homoharringtonine | ceflatonin | cgx-635 | hht | homoharringtonin | homoharringtonine | (−)-homoharringtonine | homoharringtonine, 3h-labeled, (3(r))-isomer | nsc 141633 | nsc-141633 | omacetaxine | omacetaxine mepesuccinate | synribo

Organizations (41)

Research & Development (41)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (17)

Approved Indications (2)


 

Leukemia, Myeloid, Accelerated Phase (approved 2012)

Leukemia, Myeloid, Chronic-Phase (approved 2012)

Experimental Indications - Clinical Trial Phases 1-4 (17)


 

Blast Crisis (Phase 2)

GATA2 Deficiency (Phase 1)

Hematologic Neoplasms (Phase 1)

Induction Chemotherapy (Phase 3)

Leukemia (Phase 3)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Monocytic, Acute (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid, Accelerated Phase (Phase 2)

Leukemia, Myeloid, Acute (Phase 3)

Leukemia, Myeloid, Chronic-Phase (Phase 2)

Leukemia, Myelomonocytic, Acute (Phase 2)

Lymphoma (Phase 1/Phase 2)

Mutation (Phase 2)

Myelodysplastic Syndromes (Phase 1/Phase 2)

Neoplasms ()

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 36
  • # of Trial Organizations: 41

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue